Seres Therapeutics Inc reports results for the quarter - Earnings Summary

Seres Therapeutics

13/11/2024 15:25

* Seres Therapeutics Inc  MCRB.OQ  reported quarterly
adjusted
earnings of 58 cents​​ per share for the quarter , higher than
the same quarter last year, when the company reported EPS of -37
cents.  The mean expectation of six analysts for the quarter was
for a loss of 25 cents per share. Wall Street expected
results to range from -26 cents to -23 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Seres Therapeutics Inc's reported EPS for the quarter was
58
cents​.
    * The company reported quarterly net income of $88.78
million.
    * Seres Therapeutics Inc shares had fallen by 29.8% this
quarter and lost 52.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.7%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Seres
Therapeutics Inc is 1.25 
This summary was machine generated from LSEG data November 13 at
03:25 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.25          0.58           Beat
 Jun. 30 2024                     -0.22          
 Mar. 31 2024      -0.34          -0.27          Beat
 Dec. 31 2023      -0.50          -0.32          Beat